PROTAC FGFR2 degrader 1

PROTAC FGFR2 degrader 1(compound N5)是一种有效靶向 FGFR2 的 PROTAC,DC50 为 6.46 nM,IC50 为 0.08 nM,具有抗增殖活性和高度选择性,通过降低 FGFR2 下游蛋白 p-ERK 和 p-PLCγ 的激活,诱导 KATOIII 和 SNU16 周期阻滞于 G0/G1 期,抑制细胞凋亡 (Apoptosis),并有效抑制了小鼠模型中 SNU16 异种移植肿瘤的生长(粉色: FGFR2 配体 (MS-B70517);蓝色: Cereblon 配体 (MS-Q68284);黑色: 连接子 (MS-L74568))。
产品编号: MS-V86896 CAS No.: 3099123-99-3 分子式: C46H54N10O7 分子量: 858.98
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
询价
5mg
询价
询价

产品描述

PROTAC FGFR2 degrader 1(compound N5)是一种有效靶向 FGFR2 的 PROTAC,DC50 为 6.46 nM,IC50 为 0.08 nM,具有抗增殖活性和高度选择性,通过降低 FGFR2 下游蛋白 p-ERK 和 p-PLCγ 的激活,诱导 KATOIII 和 SNU16 周期阻滞于 G0/G1 期,抑制细胞凋亡 (Apoptosis),并有效抑制了小鼠模型中 SNU16 异种移植肿瘤的生长(粉色: FGFR2 配体 (MS-B70517);蓝色: Cereblon 配体 (MS-Q68284);黑色: 连接子 (MS-L74568))。

生物实验数据

生物活性 PROTAC FGFR2 degrader 1 (compound N5) is a potent PROTAC targeting FGFR2 with a DC50 of 6.46 nM and an IC50 of 0.08 nM, possesses antiproliferative activity and high selectivity, induces G0/G1 phase arrest in KATOIII and SNU16 cells and inhibits apoptosis (Apoptosis) by reducing the activation of the FGFR2 downstream proteins p-ERK and p-PLCγ, and effectively inhibits the growth of SNU16 xenograft tumors in mice (pink: FGFR2 ligand (MS-B70517); blue: Cereblon ligand (MS-Q68284); black: linker (MS-L74568)).
IC50 & Target

FGFR2

 

Cereblon

 

体外研究
(In Vitro)

PROTAC FGFR2 degrader 1 (0-1000 nM; 72 h) 对 KATO III 和 SNU16 的 IC50 均小于 0.17 nM。
PROTAC FGFR2 degrader 1 (500 nM; 12 h; WB) 诱导 KATO III 中 FGFR2 降解,对 FGFR2 具有高度选择性,且是 UPS 依赖性的。
PROTAC FGFR2 degrader 1 (500,1000 nM; 24 h) 诱导 KATO III 和 SNU16 细胞在 G0/G1 期的细胞周期阻滞。

Western Blot Analysis

Cell Line: KATO III, SNU16
Concentration: 0, 0.1, 1, 10, 100, 500, 1000 nM
Incubation Time: 0, 1, 6, 12, 24, 36 h
Result: Degraded FGFR2 in Kato III cells with timedependent. Induced FGFR2 degradation in SNU16 cells in vivo in a mouse model. Decreased CDK2, CDK 4, Cyclin D1 and Cyclin E.

Western Blot Analysis

Cell Line: KATO III, SNU16
Concentration: 500 nM, 12 h; Pomalidomide (10 μM), Erdafitinib (10 μM), MG132 (5 μM) for 6 h; 50, 100, 500 nM for 24 h
Incubation Time: 12 h; 24 h
Result: Degraded FGFR2 via the UPS pathway, and degradation of FGFR2 was dependent on the formation of the FGFR2-N5-E3 ligase complex and subsequent proteasomal degradation. Showed that phosphorylation of p-AKT was decreased in both SNU16 and Kato III cells, inhibited the activation of p-ERK and p-PLC γ effectively.

Real Time qPCR

Cell Line: KATO III
Concentration: 500 nM
Incubation Time: 12 h
Result: Degraded FGFR2 in KATOIII with high selectivity.

Cell Cycle Analysis

Cell Line: KATO III, SNU16
Concentration: 500, 1000 nM
Incubation Time: 24 h
Result: Showed that the percentage of KATO III cells in the G0/G1 phase increased from 47.7% to 67.1% in the 1000 nM of PROTAC FGFR2 degrader 1, the number of SNU16 cells increased from 45.9% to 67.5%.

Apoptosis Analysis

Cell Line: KATO III, SNU16
Concentration: 1000 nM
Incubation Time: 24 h
Result: Showed that the apoptosis rate of KATO III cells increased from 10.9% in the DMSO group to 30.5%, upregulation of cleaved caspase 3 was observed.
体内研究
(In Vivo)

PROTAC FGFR2 degrader 1 (10 mg/kg, 20 mg/kg; Intraperitoneal injection) 在皮下异种移植 SNU16 小鼠模型中抑制胃癌细胞生长,降低肿瘤重量。
PROTAC FGFR2 degrader 1在SD大鼠体内的药动学特征

Parameters PROTAC FGFR2 degrader 1 2mg/kg(i.v.) Parameters PROTAC FGFR2 degrader 1 2mg/kg(i.p.)
t1/2 (h) 4.65±4.14 t1/2 (h) 7.59±0.365
Tmax (h) / Tmax (h) 0.25±0.177
Cmax (ng/mL) / Cmax (ng/mL) 302±33.7
MRTinf (h) 2.27±1.44 MRTinf (h) 6.53±0.0721
CL (mL/min/kg) 59.3±8.35 CL/F (mL/min/kg) 78.2±1.62
Vss (L/kg) 7.58±3.80 VZ/F (L/kg) 51.4±2.40
AUC0-t (h*ng/mL) 544±74.2 AUC0-t (h*ng/mL) 991±20.7
AUC0-inf (h*ng/mL) 570±83.3 AUC0-inf (h*ng/mL) 1066±21.9
AUC0-t/ AUC0-inf 0.956±0.0232 AUC0-t/ AUC0-inf 0.930±0.00429
F / F (%) 74.8±1.53

Animal Model: SD rats
Dosage: 2, 5 mg/kg
Administration: Intravenous injection (i.v.); Intraperitoneal injection (i.p.)
Result: Absorbed rapidly in vivo, reached its maximum concentration at 0.25 h by 5 mg/kg, and then slowly cleared from the body, with a half-life of 7.59 h.
Animal Model: A mouse model of subcutaneous xenograft of SNU16 tumor
Dosage: 10, 20 mg/kg
Administration: Intraperitoneal injection(i.p.); once daily; 25 days
Result: Showed the stronger anti-tumor effect, greater tumor growth inhibition and a significant reduction in tumor weight.
性状 固体
颜色 Light yellow to yellow

化学信息

分子量 858.98
分子式 C46H54N10O7
CAS No. 3099123-99-3

储存&溶解度

储存方式
Powder -20°C 3 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础